189 related articles for article (PubMed ID: 35316089)
1. Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Patients in Pancreatic Cancer Clinical Trials.
Riner AN; Girma S; Vudatha V; Mukhopadhyay N; Skoro N; Gal TS; Freudenberger DC; Herremans KM; George TJ; Trevino JG
J Clin Oncol; 2022 Jul; 40(20):2193-2202. PubMed ID: 35316089
[TBL] [Abstract][Full Text] [Related]
2. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival.
Heller DR; Nicolson NG; Ahuja N; Khan S; Kunstman JW
JAMA Surg; 2020 Feb; 155(2):e195047. PubMed ID: 31800002
[TBL] [Abstract][Full Text] [Related]
3. Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment.
Penberthy L; Brown R; Wilson-Genderson M; Dahman B; Ginder G; Siminoff LA
Clin Trials; 2012 Dec; 9(6):788-97. PubMed ID: 23033547
[TBL] [Abstract][Full Text] [Related]
4. Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials.
Kanapuru B; Fernandes LL; Baines A; Ershler R; Bhatnagar V; Pulte E; Gwise T; Theoret MR; Pazdur R; Fashoyin-Aje L; Gormley N
Blood; 2023 Jul; 142(3):235-243. PubMed ID: 37140031
[TBL] [Abstract][Full Text] [Related]
5. Race does not impact pancreatic cancer treatment and survival in an equal access federal health care system.
Lee S; Reha JL; Tzeng CW; Massarweh NN; Chang GJ; Hetz SP; Fleming JB; Lee JE; Katz MH
Ann Surg Oncol; 2013 Dec; 20(13):4073-9. PubMed ID: 24002535
[TBL] [Abstract][Full Text] [Related]
6. Racial and Ethnic Disparities in Primary Open-Angle Glaucoma Clinical Trials: A Systematic Review and Meta-analysis.
Allison K; Patel DG; Greene L
JAMA Netw Open; 2021 May; 4(5):e218348. PubMed ID: 34003274
[TBL] [Abstract][Full Text] [Related]
7. Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer.
Nipp R; Tramontano AC; Kong CY; Pandharipande P; Dowling EC; Schrag D; Hur C
Cancer Med; 2018 Feb; 7(2):525-535. PubMed ID: 29322643
[TBL] [Abstract][Full Text] [Related]
8. Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancreatic Consortium.
Ogobuiro I; Collier AL; Khan K; de Castro Silva I; Kwon D; Wilson GC; Schwartz PB; Parikh AA; Hammill C; Kim HJ; Kooby DA; Abbott D; Maithel SK; Snyder RA; Ahmad SA; Merchant NB; Datta J
Ann Surg Oncol; 2023 Mar; 30(3):1485-1494. PubMed ID: 36316508
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic Cancer Clinical Treatment Trials Accrual: A Closer Look at Participation Rates.
Guerra CE; Kelly S; Redlinger C; Hernández P; Glanz K
Am J Clin Oncol; 2021 Jun; 44(6):227-231. PubMed ID: 33710138
[TBL] [Abstract][Full Text] [Related]
10. Thirty-day complication rates do not differ by race among patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma.
Mitsakos AT; Dennis SO; Parikh AA; Snyder RA
J Surg Oncol; 2021 Mar; 123(4):970-977. PubMed ID: 33497474
[TBL] [Abstract][Full Text] [Related]
11. Racial and Ethnic Inequities in US Oncology Clinical Trial Participation From 2017 to 2022.
Pittell H; Calip GS; Pierre A; Ryals CA; Altomare I; Royce TJ; Guadamuz JS
JAMA Netw Open; 2023 Jul; 6(7):e2322515. PubMed ID: 37477920
[TBL] [Abstract][Full Text] [Related]
12. Racial and Ethnic Disparities in Meeting MTM Eligibility Criteria Based on Star Ratings Compared with the Medicare Modernization Act.
Spivey CA; Wang J; Qiao Y; Shih YT; Wan JY; Kuhle J; Dagogo-Jack S; Cushman WC; Chisholm-Burns M
J Manag Care Spec Pharm; 2018 Feb; 24(2):97-107. PubMed ID: 29384031
[TBL] [Abstract][Full Text] [Related]
13. Broadening Diversity in PDAC Trials.
Cancer Discov; 2021 Dec; 11(12):2951. PubMed ID: 34663596
[TBL] [Abstract][Full Text] [Related]
14. It's more than just cancer biology: Health disparities in patients with pancreatic neuroendocrine tumors.
Underwood PW; Riner AN; Neal D; Cameron ME; Yakovenko A; Reddy S; Rose JB; Hughes SJ; Trevino JG
J Surg Oncol; 2021 Dec; 124(8):1390-1401. PubMed ID: 34499741
[TBL] [Abstract][Full Text] [Related]
15. Health Disparities Impact Expected Treatment of Pancreatic Ductal Adenocarcinoma Nationally.
Lutfi W; Zenati MS; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Jul; 25(7):1860-1867. PubMed ID: 29691733
[TBL] [Abstract][Full Text] [Related]
16. Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial.
Raman R; Quiroz YT; Langford O; Choi J; Ritchie M; Baumgartner M; Rentz D; Aggarwal NT; Aisen P; Sperling R; Grill JD
JAMA Netw Open; 2021 Jul; 4(7):e2114364. PubMed ID: 34228129
[TBL] [Abstract][Full Text] [Related]
17. A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems.
Hue JJ; Katayama ES; Markt SC; Elshami M; Saltzman J; Bajor D; Hosmer A; Mok S; Dumot J; Ammori JB; Rothermel LD; Hardacre JM; Winter JM; Ocuin LM
Surgery; 2022 Jul; 172(1):257-264. PubMed ID: 34839935
[TBL] [Abstract][Full Text] [Related]
18. Racial Disparities in Endometrial Cancer Clinical Trial Representation: Exploring the Role of Eligibility Criteria.
Wolf JL; Hamilton A; An A; Leonard JP; Kanis MJ
Am J Clin Oncol; 2024 May; ():. PubMed ID: 38700907
[TBL] [Abstract][Full Text] [Related]
19. Potential Health Implications of Medication Therapy Management Eligibility Criteria in the Patient Protection and Affordable Care Act Across Racial and Ethnic Groups.
Wang J; Qiao Y; Shih YC; Jarrett-Jamison J; Spivey CA; Wan JY; White-Means SI; Dagogo-Jack S; Cushman WC; Chisholm-Burns M
J Manag Care Spec Pharm; 2015 Nov; 21(11):993-1003. PubMed ID: 26521111
[TBL] [Abstract][Full Text] [Related]
20. Mortality Disparities in Racial/Ethnic Minority Groups in the Veterans Health Administration: An Evidence Review and Map.
Peterson K; Anderson J; Boundy E; Ferguson L; McCleery E; Waldrip K
Am J Public Health; 2018 Mar; 108(3):e1-e11. PubMed ID: 29412713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]